Brokerages Set Caris Life Sciences, Inc. (NASDAQ:CAI) Target Price at $30.60

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) have been given a consensus rating of “Hold” by the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $30.60.

Several equities analysts have weighed in on CAI shares. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. BTIG Research lowered their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 27th. The Goldman Sachs Group assumed coverage on shares of Caris Life Sciences in a report on Wednesday. They issued a “buy” rating and a $27.00 target price for the company. Evercore set a $38.00 price target on shares of Caris Life Sciences in a research report on Monday, January 5th. Finally, Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th.

Caris Life Sciences Price Performance

CAI opened at $19.29 on Wednesday. The firm’s 50-day moving average is $20.19. Caris Life Sciences has a 52 week low of $16.28 and a 52 week high of $42.50. The company has a market cap of $5.45 billion and a P/E ratio of -107.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. The company’s revenue for the quarter was up 125.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.73) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC grew its position in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares in the last quarter. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $31,000. MetLife Investment Management LLC boosted its holdings in shares of Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after purchasing an additional 755 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Caris Life Sciences during the 4th quarter valued at approximately $67,000. Finally, Federated Hermes Inc. purchased a new stake in Caris Life Sciences during the 4th quarter valued at $81,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.